PALO
ALTO, Calif., May 29, 2024
/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a
biopharmaceutical company committed to researching, developing and
commercializing transformative therapeutics to treat a broad
spectrum of retinal diseases, announced today that management will
present at the following upcoming investor conferences:
- Jefferies Healthcare Conference, June 6,
2024, 8:00 AM ET (5:00 AM PT), New York,
New York
- Goldman Sachs 45th Annual Global Healthcare
Conference, June 13, 2024,
8:00 AM ET (5:00 AM PT), Miami
Beach, Florida
A live webcast of both presentations will be available on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the events.
In addition, Kodiak will participate in the upcoming Clinical
Trials at the Summit 2024 meeting, being held on June 8 from 8:00am
– 5:30pm (MT) in Park City, Utah. Presentations on Kodiak's
clinical pipeline will be given at the meeting. Specifics of the
presentations are below:
- Title: Bispecific Anti-IL-6 Anti-VEGF Programs: KSI-501 in
Retinal Vascular Disease and KSI-101 in Macular Edema Secondary to
Inflammation
Time: 7:49 – 7:53 AM MT
Presenter: Quan Dong Nguyen, M.D.,
Professor of Ophthalmology and Director of Uveitis and Ocular
Inflammation, Byers Eye Institute, Stanford
University School of Medicine.
- Title: Update on KSI Programs for Retinal Diseases
Time: 1:10 – 1:14 PM MT
Presenter: Victor Perlroth, M.D.,
Chief Executive Officer of Kodiak Sciences
Slides of these presentations will be made available on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ at the beginning of the
presentations.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company
committed to researching, developing, and commercializing
transformative therapeutics to treat a broad spectrum of retinal
diseases. We are focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Our ABC Platform™
uses molecular engineering to merge the fields of protein-based and
chemistry-based therapies and has been at the core of Kodiak's
discovery engine. We are developing a portfolio of three clinical
programs, two of which are late-stage today and derived from our
ABC Platform and one which is platform-independent and which we
believe can progress rapidly into pivotal studies.
Kodiak's lead investigational medicine, tarcocimab, is a novel
anti-VEGF antibody biopolymer conjugate under development for the
treatment of high prevalence retinal vascular diseases including
diabetic retinopathy, the leading cause of blindness in working-age
patients in the developed world, and wet age-related macular
degeneration, the leading cause of blindness in elderly patients in
the developed world.
KSI-501 is our second investigational medicine, a first-in-class
anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate
designed to inhibit both IL-6 mediated inflammation and
VEGF-mediated angiogenesis and vascular permeability. KSI-501 is
being developed for the treatment of high prevalence retinal
vascular diseases to address the unmet needs of extended durability
and targeting multiple disease biologies for differentiated
efficacy. Phase 1b data for KSI-501
was presented in February 2024, and
the Phase 3 DAYBREAK study of KSI-501 in wet AMD is scheduled to be
actively screening patients in mid-2024.
Additionally, Kodiak is developing a third product candidate,
KSI-101, a novel anti-IL-6, VEGF-trap bispecific protein, the
unconjugated protein portion of KSI-501. Kodiak intends to develop
KSI-101 for the treatment of retinal inflammatory diseases, as
currently there are no available intravitreal biologic therapies
addressing the spectrum of inflammatory conditions of the
retina.
Kodiak has expanded its early research pipeline of duet and
triplet inhibitors that embed small molecules and other active
pharmaceutical ingredients ("API") in the biopolymer backbone to
enable targeted, high drug-antibody ratio ("DAR") medicines. The
diverse API's are designed to be released over time to achieve
targeted, multi-specific and tailored modulation of biological
pathways. The unique combination of high DAR and tailored
therapeutic benefit offers potential for broad application to
multifactorial ophthalmic and systemic diseases.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-investor-and-clinical-conferences-302158588.html
SOURCE Kodiak Sciences Inc.
